VERU Stock - Veru Inc.
Unlock GoAI Insights for VERU
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | $16.89M | $16.30M | $39.35M | $61.26M |
| Gross Profit | N/A | $5.85M | $7.57M | $30.59M | $47.93M |
| Gross Margin | N/A | 34.7% | 46.4% | 77.7% | 78.2% |
| Operating Income | $9.07M | $-36,915,397 | $-93,782,216 | $-83,223,560 | $12.97M |
| Net Income | $-22,726,279 | $-37,801,426 | $-93,152,692 | $-83,776,020 | $7.39M |
| Net Margin | N/A | -223.9% | -571.6% | -212.9% | 12.1% |
| EPS | $-1.55 | $-2.80 | $-10.96 | $-10.49 | $0.97 |
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | Canaccord Genuity | Initiation | Buy | $25 |
| May 14th 2024 | B. Riley Securities | Initiation | Buy | $5 |
| March 28th 2024 | Raymond James | Initiation | Outperform | $3 |
| June 7th 2023 | Jefferies | Upgrade | Hold | $1 |
Earnings History & Surprises
VERUEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $-0.39 | — | — | — |
Q4 2025 | Dec 17, 2025 | $-0.39 | $0.05 | +112.8% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.55 | $-0.50 | +9.1% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-0.08 | $-0.07 | +12.5% | ✓ BEAT |
Q4 2024 | Dec 16, 2024 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.05 | $-0.07 | -40.0% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Q4 2023 | Dec 8, 2023 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.20 | $-0.13 | +35.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.33 | $-0.44 | -33.3% | ✗ MISS |
Q1 2023 | Feb 9, 2023 | $-0.38 | $-0.46 | -21.1% | ✗ MISS |
Q4 2022 | Dec 5, 2022 | $-0.29 | $-0.51 | -75.9% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.18 | $-0.28 | -55.6% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.16 | $-0.18 | -12.5% | ✗ MISS |
Q1 2022 | Feb 9, 2022 | $-0.11 | $-0.08 | +27.3% | ✓ BEAT |
Q4 2021 | Dec 2, 2021 | $-0.08 | $-0.05 | +37.5% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.06 | $-0.03 | +50.0% | ✓ BEAT |
Latest News
Veru FY 2025 EPS $(1.55) Beats $(1.77) Estimate
📈 PositiveVeru to Present Enobosarm Data At ObesityWeek 2025 Highlighting Lean Mass Preservation And Fat Loss Selectivity
📈 PositiveVeru announces pricing of $25 million public offering
➖ NeutralVeru Announces Pricing Of $25M Public Offering Of 1.4M Shares Of Common Stock At A Price Of $3.00 Per Unit
➖ NeutralVeru shares are trading lower after the company announced a proposed public offering.
📉 NegativeVeru announces proposed public offering
➖ NeutralVeru shares are trading lower after the company announced a proposed public offering.
📉 NegativeVeru Reveals Proposed Public Offering; No Size Disclosed
📉 NegativeVeru Secures FDA Regulatory Clarity For Enobosarm To Enhance Weight Loss With GLP-1 RA; Plans Phase 2b PLATEAU Study In Obesity Treatment
📈 PositiveVeru announces 1-for-10 reverse stock split
📉 NegativeFrequently Asked Questions about VERU
What is VERU's current stock price?
What is the analyst price target for VERU?
What sector is Veru Inc. in?
What is VERU's market cap?
Does VERU pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VERU for comparison